Fig. 3.

Targeted therapies and their combinations lead to decreased proliferation and viability in MLLr cells. Cell growth assay of (A) MLL-AF4 cells and (B) MLL-AF9 cells with assessment of cell count on days 2, 4 and 7 following treatments with 100 nM JQ-1, 10 µM MAT2Ai, 1 µM PRMT5i or the combination of JQ-1 with MAT2Ai or PRMT5i. Determination of cell viability with AlamarBlue assay of (C) MLL-AF4 and (D) MLL-AF9 cells normalized to DMSO-treated cells. Experiments were performed in n=3 biological replicates. Statistical analysis with Ordinary One-Way ANOVA in relation to DMSO-treated cells, *p < 0.05.